查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736507

全球蜱傳腦炎去活化疫苗市場規模（按病毒類型、最終用戶、區域範圍和預測）

Global Tick-Borne Encephalitis Inactivated Vaccine Market Size By Virus Type, By End User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

蜱傳腦炎去活化疫苗市場規模及預測

蜱傳腦炎去活化疫苗市場規模在 2024 年價值 3 億美元，預計到 2032 年將達到 4.8 億美元，2026 年至 2032 年的複合年成長率為 7.2%。

推動全球蜱傳腦炎去活化疫苗市場的因素

蜱傳腦炎去活化疫苗市場的促進因素可能受到多種因素的影響。這些因素包括：

盛行率和發生率：蜱傳腦炎在地方流行區和新發病區的盛行率和發生率對疫苗接種需求影響很大。發病率的上升往往促使疫苗宣傳活動加強。

認知與教育：進行公眾意識宣傳活動與教育項目，強調結核病的危害，可以影響疫苗接種需求。隨著人們對結核病及其可能後果的認知不斷提高，人們更有可能為自己和家人接種疫苗。

免疫接種計畫和政府政策：將結核病疫苗納入國家免疫接種計畫以及免疫法規的執行，可對消費者需求產生重大影響。疫苗接種回扣和補貼也有助於鼓勵接種。

旅行和旅遊業趨勢：與旅行相關的商務旅行 (TBE) 很常見，尤其是在歐洲和亞洲部分地區。前往這些地區的旅行和旅遊業成長可能會導致尋求結核病疫苗接種的旅客需求增加。

研發：發展的動力將是疫苗技術的開發，以提高疫苗的安全性、有效性和給藥的便利性，使疫苗接種更加可靠，並為更多的人接種疫苗。

疫情爆發和流行：如果爆發結核病，這可能會導致社會焦慮加劇，並增加人們對接種疫苗的需求，因為人們會嘗試接種疫苗來預防這種疾病。

氣候變遷和生態學因素：傳播結核病的蜱蟲的分佈和流行程度可能因氣候和生態學因素的變化而改變，從而可能擴大該疾病的地理範圍並增加以前未受影響地區的疫苗接種需求。

醫療保健基礎設施：疫苗接種覆蓋率和市場需求可能會受到醫療保健基礎設施的可近性和可用性的影響，例如疫苗接種診所和有資格接種結核病疫苗的醫療保健人員。

保險覆蓋範圍：結核性腦炎疫苗的保險覆蓋範圍和報銷政策可能會影響疫苗的可用性和可負擔性，進而影響市場需求。

限制全球去活化蜱傳腦炎疫苗市場的因素

蜱傳腦炎去活化疫苗市場可能面臨多種限制和挑戰，包括：

教育和認知不足：公眾對蜱傳疾病和疫苗獲取管道的無知可能會阻礙該行業的擴張。在結核病不常見的地區，由於缺乏對危害的認知，疫苗需求可能會減少。

地域限制：結核病主要流行於亞洲和歐洲部分地區。結核病發病率較低的地區對疫苗的需求可能有限，這可能會阻礙市場擴張。

經濟因素：經濟因素可能會阻礙疫苗的取得，尤其是在低收入國家。疫苗宣傳活動的成本以及疫苗本身也可能阻礙疫苗的普及，尤其是在醫療保健服務匱乏的地區。

監管障礙：疫苗分發和核准的嚴格監管可能會阻礙市場擴張。在許多國家和地區，疫苗製造商獲得監管部門的批准既昂貴又耗時。

疫苗接種猶豫：對疫苗有效性和安全性的錯誤訊息和擔憂都可能導致接種猶豫，從而影響結核病疫苗的接種率並阻礙市場擴張。

與其他預防措施的競爭：疫苗的引入可能面臨其他預防措施的競爭，如穿防護衣、使用驅蟲劑等。此外，競爭疫苗和不同的預防結核病的方法可能會限制市場擴張。

季節性：結核病發生率通常在蜱蟲最活躍的某些季節上升。由於這種季節性，疫苗的市場需求可能會在全年波動。

供應鏈問題：疫苗的生產、配送和儲存可能非常複雜，並可能為市場參與企業帶來問題。在結核病流行地區，尤其是在偏遠或資源匱乏的地區，維持穩定的供應鏈可能非常困難。

目錄

第1章 去活化蜱傳腦炎疫苗的全球市場介紹

  • 市場採用
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

4. 蜱傳腦炎去活化疫苗的全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球去活化蜱傳腦炎疫苗市場（依病毒類型分類）

  • 概述
  • 西伯利亞TBE病毒
  • 遠東TBE病毒
  • 歐洲TBE病毒

6. 全球蜱傳腦炎去活化疫苗市場（依最終用戶）

  • 概述
  • 旅行者疫苗
  • 兒童疫苗
  • 成人疫苗

7. 全球去活化蜱傳腦炎疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

8. 全球蜱傳腦炎去活化疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第9章 公司簡介

  • GlaxoSmithKline plc.
  • London Travel Clinic
  • Superdrug Health Clinic
  • Pfizer Inc.
  • Encephalitis Global, Inc
  • The Cochrane Collaboration
  • Sonic HealthPlus Pty Ltd
  • Merck & Co., Inc
  • Baxter International Inc
  • Hawaii BIoTech, Inc

第10章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 37205

Tick-Borne Encephalitis Inactivated Vaccine Market Size And Forecast

Tick-Borne Encephalitis Inactivated Vaccine Market size was valued at USD 300 Million in 2024 and is projected to reach USD 480 Million by 2032, growing at a CAGR of 7.2% during the forecast period 2026-2032.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Drivers

The market drivers for the Tick-Borne Encephalitis Inactivated Vaccine Market can be influenced by various factors. These may include:

Prevalence and Incidence: The demand for vaccinations can be strongly influenced by the prevalence and incidence of TBE in areas where it is endemic or emerging. Increasing incidence rates frequently prompts more immunization campaigns.

Awareness and Education: Vaccination demand may be influenced by public awareness campaigns and educational programs highlighting the dangers of TBE. People may seek vaccinations for themselves and their families as they become more aware of the illness and its possible effects.

Immunization Programs and Government Policies: Including TBE vaccines in national immunization programs or enforcing vaccination laws can have a significant impact on consumer demand. Reimbursements or subsidies for the cost of vaccinations might also encourage uptake.

Travel and Tourism Trends: Travel-related business travel (TBE) is common in several areas, especially in portions of Europe and Asia. Travelers seeking protection against the disease may find a greater need for TBE vaccinations as a result of increased travel and tourism to these regions.

Research and Development: By boosting vaccination confidence and reaching a wider audience, developments in vaccine technology, such as those that enhance safety, efficacy, and convenience of administration, can propel market expansion.

Outbreaks and Epidemics: When TBE occurs, there may be a surge in public anxiety and a need for vaccinations as people try to vaccinate against the illness.

Climate Change and Ecological Factors: TBE-carrying tick distribution and prevalence can be altered by changes in climate and ecological factors. This could lead to an expansion of the disease's geographic range and a greater requirement for immunization in previously unaffected areas.

Healthcare Infrastructure: Vaccination rates and market demand may be impacted by the accessibility and availability of healthcare infrastructure, such as vaccination clinics and medical personnel qualified to give TBE vaccines.

Insurance Coverage: A TBE vaccination's insurance coverage and reimbursement policies may have an impact on accessibility and affordability, which in turn may have an effect on market demand.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Restraints

Several factors can act as restraints or challenges for the Tick-Borne Encephalitis Inactivated Vaccine Market. These may include:

Limited Education and Awareness: The general public's ignorance about tick-borne illnesses and the accessibility of vaccines can impede the expansion of the industry. There might not be as much demand for the vaccine in areas where TBE is uncommon because of a lack of knowledge about the hazards.

Geographic Restrictions: TBE is mostly endemic in some parts of Asia and Europe. The demand for the vaccine may be restricted in regions with low incidence of TBE, which could hinder efforts to expand the market.

Economic Factors: Access to vaccines may be hampered by financial limitations, especially in low-income nations. Adoption may be hampered by the expense of immunization campaigns and the vaccine itself, particularly in areas with little access to healthcare.

Regulatory Obstacles: Tight regulations pertaining to vaccination distribution and approval may impede market expansion. For vaccine producers, obtaining regulatory clearances in many nations and areas can be expensive and time-consuming.

Vaccine reluctance: Misinformation and worries about the effectiveness and safety of vaccines can all lead to vaccination reluctance. This may have an effect on TBE vaccination uptake and impede market expansion.

Competition from Other Preventive Measures: The adoption of vaccines may face competition from other preventive measures like wearing protective clothing and using insect repellents. Furthermore, rival vaccinations or different methods of preventing TBE could restrict market expansion.

Seasonality: When tick activity is at its highest, TBE incidence frequently rises during specific seasons. The market demand for vaccinations may fluctuate throughout the year as a result of this seasonality.

Supply Chain Difficulties: Vaccine manufacture, delivery, and storage can be complicated, which might present problems for market participants. It might be challenging to keep a steady supply chain when TBE is common, particularly in isolated or resource-constrained places.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Segmentation Analysis

The Global Tick-Borne Encephalitis Inactivated Vaccine Market is segmented on the basis of Virus Type, End User, And Geography.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Virus Type

  • Siberian TBE Virus
  • Far Eastern TBE Virus
  • European TBE Virus

Based on Virus Type, The market is segmented into Siberian TBE Virus, Far Eastern TBE Virus, and European TBE Virus. The three types of TBEV are TBEV-European, TBEV-Siberian, and TBEV-Far Eastern (previously Russian spring-summer encephalitis virus), which differ in geography and disease presentation. TBEV usually causes febrile disease, which may be followed by severe neurological disorders, such as encephalitis and meningitis. Some virus strains, like TBEV-Far Eastern, have a high mortality rate, and many survivors suffer from long-term sequelae.

Tick-Borne Encephalitis Inactivated Vaccine Market, By End User

  • Traveler Vaccines
  • Pediatric Vaccines
  • Adult Vaccines

Based on End User, The market is segmented into Traveler Vaccines, Pediatric Vaccines and Adult Vaccines. Travelers who anticipate high-risk exposures, such as working or camping in forested regions or farmland, adventurous travel, or long stays in TBE-endemic nations.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Regional Analysis, The Global Tick-Borne Encephalitis Inactivated Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. TBE is endemic in a few areas in Europe and Asia, ranging from eastern France to northern Japan, and from northern Russia to Albania. The country with the most reported cases is Russia. Western Siberia, Slovenia, and the Baltic States have recorded the highest disease incidence.

Key Players

  • The major players in the Tick-Borne Encephalitis Inactivated Vaccine Market are:
  • GlaxoSmithKline plc.
  • London Travel Clinic
  • Superdrug Health Clinic
  • Pfizer Inc.
  • Encephalitis Global Inc.
  • The Cochrane Collaboration
  • Sonic HealthPlus Pty Ltd.
  • Merck & Co. Inc.
  • Baxter International Inc.
  • Hawaii Biotech Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY VIRUS TYPE

  • 5.1 Overview
  • 5.2 Siberian TBE Virus
  • 5.3 Far Eastern TBE Virus
  • 5.4 European TBE Virus

6 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, END USER

  • 6.1 Overview
  • 6.2 Traveler Vaccines
  • 6.3 Pediatric Vaccines
  • 6.4 Adult Vaccines

7 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 GlaxoSmithKline plc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 London Travel Clinic
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Superdrug Health Clinic
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Pfizer Inc.
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Encephalitis Global, Inc
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 The Cochrane Collaboration
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Sonic HealthPlus Pty Ltd
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Merck & Co., Inc
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Baxter International Inc
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Hawaii Biotech, Inc
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research